High-dose intravenous methylprednisolone for acute childhood idiopathic thrombocytopenic purpura.
49 children with acute idiopathic thrombocytopenic purpura (ITP) were divided into non-treatment, oral prednisone (2 mg/kg), and high-dose intravenous methylprednisolone (HIVMP) treatment groups which consisted of 17, 16 and 16 children respectively. Platelet counts rose above 150,000/microliters over a 2-week period in 5 (29.4%) children in the first group, 5 (31.2%) in the second group and 15 (93.7%) children in the third group. Platelet counts reached the normal level in only 3 days in 11 (68.7%) children treated with HIVMP. Initially, antiplatelet antibodies (APA) were shown by the Handin and Stossel method in every patient. With normalization of platelet counts, the antibodies decreased but could still be detected in every case; antibody decrease was greater in the HIVMP group. With the exception of mild cushingoid appearance, none of the major corticosteroid side effects was observed in the treated children.
Ozsoylu
S
S
Hacettepe University Faculty of Medicine, Department of Pediatrics, Ankara, Turkey.
Irken
G
G
Karabent
A
A
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D010976:Platelet Count / Q000187:drug effects; D011241:Prednisone / Q000008:administration & dosage; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
D011241:Prednisone; D008775:Methylprednisolone